The challenge is considered one of the toughest bottlenecks in modern drug development. Despite major advances, the oral administration of peptides remains severely limited by low permeability and rapid transport in the digestive tract. If a solution could be found, bioavailability and drug absorption could be significantly increased, making treatment easier and more tolerable for patients. BioMed X relies on its global talent model, in which young researchers from all over the world submit ideas and selected teams in Heidelberg put the concepts into practice. Applications for the new research group are open until 12 October 2025. Novo Nordisk is contributing its experience as a pioneer of the first oral peptide therapies and hopes that the project will boost innovation in drug development.
The alliance underlines the growing importance of partnerships between independent research institutes and pharmaceutical companies. For both partners, it opens up the opportunity to create a new generation of oral peptide drugs that could have a lasting impact on everyday medical practice.
News of the "bioRN Network e.V." from 19.08.2025
